Aurinia Pharmaceuticals (NASDAQ:AUPH) & BeOne Medicines (NASDAQ:ONC) Head to Head Analysis

Aurinia Pharmaceuticals (NASDAQ:AUPH) and BeOne Medicines (NASDAQ:ONC) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Aurinia Pharmaceuticals and BeOne Medicines, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0	4	2	0	2.33
BeOne Medicines	1	1	11	2	2.93

Aurinia Pharmaceuticals presently has a consensus target price of $17.25, suggesting a potential downside of 1.60%. BeOne Medicines has a consensus target price of $390.00, suggesting a potential upside of 43.49%. Given BeOne Medicines’ stronger consensus rating and higher probable upside, analysts plainly believe BeOne Medicines is more favorable than Aurinia Pharmaceuticals.

Volatility and Risk

Aurinia Pharmaceuticals has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500.

Earnings & Valuation

This table compares Aurinia Pharmaceuticals and BeOne Medicines”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$298.30 million	7.56	$287.20 million	$2.17	8.08
BeOne Medicines	$5.34 billion	5.58	$286.93 million	$4.47	60.81

Aurinia Pharmaceuticals has higher earnings, but lower revenue than BeOne Medicines. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are owned by company insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Aurinia Pharmaceuticals and BeOne Medicines’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%
BeOne Medicines	8.94%	12.06%	6.69%

Summary

BeOne Medicines beats Aurinia Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.